Home Funding Canadian biotech startup Gandeeva Therapeutics raises USD 40 million in Series A

Canadian biotech startup Gandeeva Therapeutics raises USD 40 million in Series A

Canada-based Gandeeva Therapeutics, a rapidly growing biotechnology company focused on drug discovery and development through cryo-EM technology and machine learning, raised USD 40 million on 31st January 2022.

Investors: The investment round was co-led by Lux Capital and Leaps by Bayer, backed by several investors, including Obvious Ventures, Amgen Ventures, Amplitude Ventures, and Air Street Capital.

Purpose of funding: Using the funding, the startup plans to accelerate the development of novel precision medicines using Gandeeva’s AI-driven cryo-EM platform. By integrating biochemistry, structural biology, imaging, and machine learning, this platform enables the atomic-level analysis of protein-drug interactions. The goal is to provide new knowledge about protein function.

About Gandeeva Therapeutics

Founded in 2021 by Dr Sriram Subramaniam, Gandeeva Therapeutics is located in Vancouver, Canada. Gandeeva Therapeutics is a rapidly growing biotechnology company focused on drug discovery and development through cryo-EM technology and machine learning. Its AI-driven platform visualizes and analyzes protein-drug interactions at unprecedented speed and atomic detail. This platform enables breakthroughs in precision medicine. Its cryo-EM, a drug discovery platform, uses structural and biochemical properties of protein sites in conjunction with tools to focus on these sites with greater precision, allowing patients to receive faster and more affordable treatment. The startup’s mission is to bring new treatment options to patients by revolutionizing drug discovery.

What the founder has to say

“For decades, we have known that understanding the language by which proteins are folded, and function in the native context of the cell is fundamental to deciphering biology. Altered protein function is implicated in nearly every disease,” said Dr Sriram Subramaniam, Founder and CEO, Gandeeva Therapeutics.

“Gandeeva endeavours to unlock these mysteries by moving beyond recent developments in cryo-EM technology and in AI-driven approaches to structural biology by integrating these technologies in its pioneering platform. I’m thrilled to be leading an interdisciplinary and diverse team of biologists, chemists, microscopists, and engineers to achieve this shared mission.”

What the investors have to say

“We are excited about Gandeeva’s platform and its potential to combine prediction and experimentation to optimize drug design by visualizing protein-drug interactions and analyzing at the level of atoms, with unprecedented speed,” said Jürgen Eckhardt, Head of Leaps by Bayer.

“Gandeeva’s focus on applying their powerful technologies to improve drug development dramatically is aligned with our ambition to transform health with data, enabling breakthroughs in precision medicine and beyond.”

“The combination of cryo-EM and AI is unlocking and democratizing atomic resolution at scale, and Gandeeva’s platform and the team sit squarely at the interface of these two technologies,” said Adam Goulburn, Partner at Lux Capital.

“By digitizing and automating cryo-EM imaging, Gandeeva is leading the transformation of structural biology-led drug discovery.”


 For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our 2022 best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article

Previous articleIndonesian fintech startup Ayoconnect raises USD 15 million in Series B
Next articleEgypt-based social commerce platform Brimore raises USD 25 million in Series A
Varun Nath writes about the startup ecosystem on VC Bay. A student at Delhi University, he is pursuing a Bachelor of Commerce degree. In pursuit of exploring the world of finance and technology. You can reach him at varunnath155@gmail.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here